Table 1.
Common toxicity values used in risk assessment for dose-response assessment
| Toxicity Valuesa | Definition | Population Variability Addressed? |
|---|---|---|
|
NOAEL: No Observed Adverse Effect Level |
The highest exposure level at which there are no biologically significant increases in the frequency or severity of adverse effect between the exposed population and its appropriate control. | No. |
|
BMD(L): Benchmark Dose (Lower confidence limit) |
A dose of a substance that when ingested produces a predetermined change (“benchmark response”) in the response rate of an adverse effect relative to the background response rate of this effect. | No. |
|
RfD: Reference Dose |
An estimate of the dose of a substance (with uncertainty spanning perhaps an order of magnitude) to which a human population can be exposed (including sensitive subgroups) that is likely to be without an appreciable risk of deleterious effects during a lifetime. | Uncertainty factor (10-fold) for human variability. |
|
MRL: Minimal Risk Level |
An estimate of the daily human exposure to a hazardous substance that is likely to be without appreciable risk of adverse non-cancer health effects over a specified duration of exposure. | Uncertainty factor (10-fold) for human variability. |
|
OSF: Oral Slope Factor |
An upper-bound estimate of risk per increment of oral dose that can be used to estimate risk probabilities for different exposure levels. | Increased risk at early life stages for mutagenic compounds. |
|
OED(L): Oral Equivalent Dose (Lower confidence limit) |
Daily oral dose necessary to produce steady-state in vivo blood concentrations equivalent to the AC50 (concentration at 50% of maximum activity) or LEC (lowest effective concentration) values in the in vitro assays. | Modeled toxicokinetic variability. |
|
HDMI: “Target Human Dose” for a specific Magnitude and Incidence |
The human dose at which a fraction I of the population shows an effect of magnitude (or severity) M or greater (for the critical effect considered). | Probabilistic factor separately addressing variability and uncertainty. |
Sources: (ATSDR 2013; U.S. EPA 1989, 2002., 2005., 2012; Wetmore 2015; WHO/IPCS 2014)
A numerical expression of the dose-response relationship that, when combined with exposure, gives information to characterize risk.